Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
Go back to Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile| ARISTOTLE (NASDAQ: ARTL) | Delayed: 1.36 +0.04 (3.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.32 | 52 Week High | $6.22 | |||
| Open | $1.31 | 52 Week Low | $2.74 | |||
| Day High | $1.37 | P/E | N/A | |||
| Day Low | $1.29 | EPS | $-0.21 | |||
| Volume | 317,191 | |||||
